Literature DB >> 815819

Kappa-chain deficiency. An immunoglobulin disorder.

B J Zegers, W J Maertzdorf, E Van Loghem, N A Mul, J W Stoop, J Van Der Laag, J J Vossen, R E Ballieux.   

Abstract

Since kappa-chain deficiency is an unusual condition, we studied the clinical and laboratory findings in a patient with this deficiency. The patient had cystic fibrosis with concurrent malabsorption, diabetes mellitus and IgA deficiency. The serum levels of IgM and IgG were 0.85 and 7.22 mg per milliliter, respectively. Kappa type IgM and IgG was not present in serum and external secretions; gamma, mu and lambda chains were probably polyclonal in character. Antibodies against kappa chains were not detected in either the patient or the mother. Plasma cells containing kappa-type immunoglobulins were absent in jejunum samples and bone marrow; kappa-chainbearing B lymphocytes could not be detected in blood and bone marrow. The serum of one of the patient's sisters contained trace amounts of kappa-type immunoglobulins. The patient displays a complete absence of kappa-type immunoglobulins, probably owing to a genetic defect.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 815819     DOI: 10.1056/NEJM197605062941902

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  9 in total

Review 1.  Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia.

Authors:  Aaron E Foster; Malcolm K Brenner; Gianpietro Dotti
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

2.  Selective deficiency of immunoglobulin A2.

Authors:  E van Loghem; B J Zegers; E J Bast; L Kater
Journal:  J Clin Invest       Date:  1983-12       Impact factor: 14.808

Review 3.  Engineered T cells: the promise and challenges of cancer immunotherapy.

Authors:  Andrew D Fesnak; Carl H June; Bruce L Levine
Journal:  Nat Rev Cancer       Date:  2016-08-23       Impact factor: 60.716

4.  T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.

Authors:  Juan Vera; Barbara Savoldo; Stephane Vigouroux; Ettore Biagi; Martin Pule; Claudia Rossig; Jessie Wu; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Gianpietro Dotti
Journal:  Blood       Date:  2006-08-22       Impact factor: 22.113

5.  Immunoglobulin levels, immunodeficiency and HLA in type 1 (insulin-dependent) diabetes mellitus.

Authors:  S Hoddinott; J Dornan; J C Bear; N R Farid
Journal:  Diabetologia       Date:  1982-10       Impact factor: 10.122

6.  Aberrant recombination events in B cell lines derived from a kappa-deficient human.

Authors:  J Stavnezer; O Kekish; D Batter; J Grenier; I Balazs; E Henderson; B J Zegers
Journal:  Nucleic Acids Res       Date:  1985-05-24       Impact factor: 16.971

7.  Light chain editing in kappa-deficient animals: a potential mechanism of B cell tolerance.

Authors:  E L Prak; M Trounstine; D Huszar; M Weigert
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

Review 8.  Adoptive T-cell therapy for Leukemia.

Authors:  Haven R Garber; Asma Mirza; Elizabeth A Mittendorf; Gheath Alatrash
Journal:  Mol Cell Ther       Date:  2014-08-12

9.  Combinatorial CAR design improves target restriction.

Authors:  Hakan Köksal; Pierre Dillard; Asta Juzeniene; Gunnar Kvalheim; Erlend B Smeland; June H Myklebust; Else Marit Inderberg; Sébastien Wälchli
Journal:  J Biol Chem       Date:  2020-12-03       Impact factor: 5.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.